Lipoxygenase inhibitors patent

Lipoxygenase inhibitors

Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.

Publication details

Recorded assignee: SRI International
Publication number: US 12741926 B2
Publication type: Utility patent grant
Publication date: Sep 22, 2026
Filing date: Dec 18, 2020
CPC classes: C07C217/86, C07D401/12, C07C211/49, C07C211/50, C07C211/53, C07C211/54, C07C211/56, C07C215/80, C07C215/82, C07C217/92, C07D209/08, C07D209/14, C07D213/74, C07D215/24, C07D215/38, C07D231/12, C07D233/64, C07D249/08, C07D257/04, C07D295/125, C07D295/13, C07D305/06, C07D305/08, C07D309/04, C07D403/06, C07D403/12, C07D405/06, C07D405/12, C07D405/14, C07D409/12, C07D413/12, C07D417/12
Inventors: Jong; Ling, Collins; Nathan, Ng; Raymond

Party names reflect the published document. Current ownership and legal status can change.

View patent publication →